Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1997-11-19
|
pubmed:abstractText |
Specific activation of resting lymphocytes for tumor targeting can be achieved by bispecific monoclonal antibodies (bi-mAb) with specificity for tumor antigens and T-cell-activating antigens, respectively, in combination with a costimulatory anti-CD28 antibody. We describe the generation and function of a bi-mAb with specificity for CD3 and for the tumor antigen CA19-9. The bi-mAb OKT3/NSI19-9 was generated by somatic fusion of two hybridoma lines secreting antibodies against CA19-9 and CD3, respectively. A hybrid/hybridoma was established, and its bi-mAb was characterized. In combination with a costimulatory anti-CD28 mAb resting peripheral lymphocytes could be activated specifically with T-cell proliferation and secretion of high amounts of interferon-gamma. On specific T-cell activation, bi-mAb OKT3/NSI19-9 could also redirect the cytotoxic effects of these T cells toward CA19-9+ tumor cells in vitro. Our results indicate that specific activation of resting T cells with bi-mAb OKT3/NSI19-9 in combination with an anti-CD28 mAb can activate resting T cells specifically and leads to antigen-dependent bi-mAb-mediated cytotoxicity against CA19-9+ target cells. This approach may offer new perspectives for the specific immunotherapy of CA19-9+ tumors.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Bispecific,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD28,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD3,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/CA-19-9 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Muromonab-CD3
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1524-9557
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
325-33
|
pubmed:dateRevised |
2008-3-18
|
pubmed:meshHeading |
pubmed-meshheading:9336739-Antibodies, Bispecific,
pubmed-meshheading:9336739-Antibodies, Monoclonal,
pubmed-meshheading:9336739-Antigens, CD28,
pubmed-meshheading:9336739-Antigens, CD3,
pubmed-meshheading:9336739-Antigens, Neoplasm,
pubmed-meshheading:9336739-CA-19-9 Antigen,
pubmed-meshheading:9336739-Colorectal Neoplasms,
pubmed-meshheading:9336739-Flow Cytometry,
pubmed-meshheading:9336739-Humans,
pubmed-meshheading:9336739-Immunotherapy, Adoptive,
pubmed-meshheading:9336739-Lymphocyte Activation,
pubmed-meshheading:9336739-Lymphocytes, Tumor-Infiltrating,
pubmed-meshheading:9336739-Muromonab-CD3,
pubmed-meshheading:9336739-Tumor Cells, Cultured
|
pubmed:year |
1997
|
pubmed:articleTitle |
Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
|
pubmed:affiliation |
Klinik I für Innere Medizin der Universität zu Köln, Germany.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|